Recent advances in the development of novel protein scaffolds based therapeutics
- 1 September 2017
- journal article
- review article
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 102, 630-641
Abstract
No abstract availableKeywords
This publication has 115 references indexed in Scilit:
- Tumor-Targeting Antibody–Anticalin Fusion Proteins for in Vivo Pretargeting ApplicationsBioconjugate Chemistry, 2013
- Bispecific Designed Ankyrin Repeat Proteins (DARPins) Targeting Epidermal Growth Factor Receptor Inhibit A431 Cell Proliferation and Receptor RecyclingJournal of Biological Chemistry, 2011
- Adnectins: engineered target-binding protein therapeuticsProtein Engineering, Design and Selection, 2010
- An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodiesProceedings of the National Academy of Sciences, 2009
- Engineered Cystine-Knot Peptides that Bind αvβ3 Integrin with Antibody-Like AffinitiesJournal of Molecular Biology, 2009
- Knottin cyclization: impact on structure and dynamicsBMC Structural Biology, 2008
- The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancerBMC Cancer, 2008
- A Designed Ankyrin Repeat Protein Evolved to Picomolar Affinity to Her2Journal of Molecular Biology, 2007
- Ankyrin Repeat: A Unique Motif Mediating Protein−Protein InteractionsBiochemistry, 2006
- Engineered antibody fragments and the rise of single domainsNature Biotechnology, 2005